ArticleThe oncologist2021

FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.

Filippo Pietrantonio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.